Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies

LAUSANNE, Switzerland and SAN FRANCISCO, May 4, 2022 /PRNewswire/ -- Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson's...

Click to view original post